Difference between revisions of "Pazopanib (Votrient)"
m |
m |
||
| Line 24: | Line 24: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 10 | + | * 2009-10-19: Initial FDA approval for the treatment of patients with advanced [[Renal cell carcinoma | renal cell carcinoma]]. ''(Based on VEG105192)'' |
| − | * | + | * 2012-04-26: New indication for patients with advanced [[Soft tissue sarcoma | soft tissue sarcoma]] who have received prior chemotherapy. The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. ''(Based on PALETTE)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2010-06-14: Initial marketing authorization as Votrient. |
==Also known as== | ==Also known as== | ||
*'''Code name:''' GW786034B | *'''Code name:''' GW786034B | ||
| + | *'''Generic name:''' pazopanib hydrochloride | ||
*'''Brand name:''' Pazopater, Votrient | *'''Brand name:''' Pazopater, Votrient | ||
Revision as of 23:41, 4 May 2023
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
- Angiosarcoma
- Soft tissue sarcoma
- Thyroid cancer
Patient drug information
- Pazopanib (Votrient) package insert[1]
- Pazopanib (Votrient) patient drug information (Chemocare)[4]
- Pazopanib (Votrient) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2009-10-19: Initial FDA approval for the treatment of patients with advanced renal cell carcinoma. (Based on VEG105192)
- 2012-04-26: New indication for patients with advanced soft tissue sarcoma who have received prior chemotherapy. The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. (Based on PALETTE)
History of changes in EMA indication
- 2010-06-14: Initial marketing authorization as Votrient.
Also known as
- Code name: GW786034B
- Generic name: pazopanib hydrochloride
- Brand name: Pazopater, Votrient
References
- Drugs
- Oral medications
- FGFR inhibitors
- KIT inhibitors
- PDGFR inhibitors
- SRC inhibitors
- VEGFR inhibitors
- Angiosarcoma medications
- Ovarian cancer medications
- Renal cell carcinoma medications
- Soft tissue sarcoma medications
- Desmoid tumor medications
- Gastrointestinal stromal tumor medications
- Thyroid cancer, differentiated medications
- EMA approved in 2010
- FDA approved in 2009